ArticleFrontiers in oncology2025
Establishment and validation of a nomogram model for predicting early death in patients with endometrial cancer bone metastases.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with endometrial cancer bone metastases (ECBM) are clinically rare and have a poor prognosis, including a higher incidence of early death (survival ≤ 3 months). Currently, no practical tools exist to predict early mortality in these patients. Thus, there is an urgent need to develop clinically applicable predictive models, such as nomograms, for individualized assessment of early death risk in ECBM. Methods: Relevant clinical and pathological data for ECBM patients from the SEER database (2010-2021). Univariate and multivariate logistic regression analyses were performed to identify risk factors associated with early death in ECBM patients and to construct prognostic nomograms. ROC analysis, calibration curves, and decision curve analysis (DCA) were used to assess the predictive accuracy and clinical utility of the nomogram model. Results: A total of 1,201 ECBM patients were found in the SEER database. After applying strict exclusion criteria, 769 patients were finally included in this study. Patients were randomly divided into training and validation cohorts in a 7:3 ratio. The results of univariate and multivariate logistic regression analyses revealed several independent predictive factors for early death. For both overall early death (OED) and cancer-specific early death (CSED), protective factors included surgery (OED: OR = 0.22, 95%CI: 0.12-0.41, p<0.001; CSED: OR = 0.33, 95%CI: 0.18-0.61, p<0.001) and chemotherapy (OED: OR = 0.11, 95%CI: 0.06-0.18, p<0.001; CSED: OR = 0.14, 95%CI: 0.09-0.24, p<0.001). Brain metastases increased risk (OED: OR = 2.98, 95%CI: 1.29-6.87, p=0.01; CSED: OR = 2.20, 95%CI: 1.04-4.79, p=0.047). Compared to 0-9 days, longer time from diagnosis to treatment showed protective associations: 10-27 days (OED: OR = 0.51, 95%CI: 0.27-0.98, p=0.042) and ≥28 days (OED: OR = 0.23, 95%CI: 0.12-0.44, p<0.001; CSED: OR = 0.30, 95%CI: 0.16-0.56, p<0.001). Regarding histological type, compared to endometrioid subtype, sarcomatous subtype significantly increased OED risk (OR = 3.04, 95%CI: 1.40-6.57, p=0.005), while radiotherapy reduced CSED risk (OR = 0.55, 95%CI: 0.33-0.92, p=0.022). Based on these variables, nomograms were developed to predict the risk of early death. The ROC curve confirmed the model's high predictive accuracy, while the calibration curve showed strong alignment between predicted and actual survival. DCA further demonstrated its clinical utility. Conclusion: In this study, we developed robust nomogram models to predict the probability of early death in ECBM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.